After a long wait, it appears FDA and the World Health Organization have both made decisions about biosimilar naming conventions.
FDA’s policy has yet to be released and the WHO policy is a draft, but they at least will provide some direction for sponsors, including those looking to use the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?